Safety of Prohemostatic Interventions

Abstract

Pharmacological prohemostatic agents may be useful adjunctive treatment options in patients with severe blood loss. The efficacy of these interventions has been established in a variety of clinical situations. However, the procoagulant effect of these interventions may tip the balance toward a higher risk of thrombotic complications. Several studies have shown that some prohemostatic interventions may indeed increase the risk of arterial and venous thromboembolism, although these complications are relatively rare. When considering the use of adjunctive prohemostatic agents to prevent or treat excessive blood loss, the risk of thrombotic complications should be taken into account.

Keywords

prohemostatic drugs - desmopressin - prothrombin complex concentrate - recombinant factor VIIa - aprotinin - lysine analogs

• References

• 1 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
• 2 Levi M. Critical bleeding in surgery: conventional therapy and new prospects. Minerva Anestesiol 2004; 70 (5) 267-271
• 3 Levi M, Vink R, de Jonge E. Prevention and treatment of bleeding by pro-hemostatic treatment strategies. Wien Med Wochenschr 2003; 153 (19-20) 421-425
• 4 Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ ; American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 110S-112S
• 5 Levi MM, Eerenberg E, Löwenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68 (2) 68-76
• 6 Levi M, Eerenberg E, Kamphuisen PW. Periprocedural reversal and bridging of anticoagulant treatment. Neth J Med 2011; 69 (6) 268-273
• 7 Caplan SN, Berkman EM. Letter: Protamine sulfate and fish allergy. N Engl J Med 1976; 295 (3) 172
• 8 Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 1997; 13 (4) 394-397
• 9 Mauney MC, Buchanan SA, Lawrence WA , et al. Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg 1995; 22 (3) 264-269, discussion 269–270
• 10 Dellagrammaticas D, Lewis SC, Gough MJ ; GALA Trial Collaborators. Is heparin reversal with protamine after carotid endarterectomy dangerous?. Eur J Vasc Endovasc Surg 2008; 36 (1) 41-44
• 11 Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4 (9) 1853-1863
• 12 Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 1998; 12 (2) 91-98
• 13 Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998; 158 (19) 2136-2140
• 14 Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115 (1) 145-149
• 15 Crowther MA, Douketis JD, Schnurr T , et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137 (4) 251-254
• 16 Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163 (20) 2469-2473
• 17 Martin JC. Anaphylactoid reactions and vitamin K. Med J Aust 1991; 155 (11-12) 851
• 18 Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11 (2) 175-183
• 19 Dentali F, Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica 2004; 89 (7) 857-862
• 20 Aguilar MI, Hart RG, Kase CS , et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82 (1) 82-92
• 21 Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77 (3) 477-480
• 22 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
• 23 Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83 (2) 137-143
• 24 Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33 (4) 883-890
• 25 Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103 (2) 228-239
• 26 Löwenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010; 68 (6) 242-251
• 27 McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336 (8723) 1137-1138
• 28 Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6 (1) 11-14
• 29 Miesbach W, Krekeler S, Dück O , et al. Clinical assessment of efficacy and safety of DDAVP. Hamostaseologie 2010; 30 (Suppl. 01) S172-S175
• 30 Perry D, Berntorp E, Tait C , et al. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. Haemophilia 2010; 16 (1) 80-89
• 31 Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2 (10) 1700-1708
• 32 Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16 (2) 263-271
• 33 Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) S107-S111
• 34 Friederich PW, Levi M, Bauer KA , et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103 (21) 2555-2559
• 35 Hoffman M, Monroe III DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S61-S65
• 36 Mayer SA, Brun N, Broderick J , et al. Recombinant factor via for acute intracerebral hemorrhage. Proceedings 5th World Stroke Congress 2004;Vancouver, 26 June 2004
• 37 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (3) 293-298
• 38 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
• 39 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339 (4) 245-253
• 40 van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99 (5) 788-796, discussion 796–797
• 41 Levi M, Cromheecke ME, de Jonge E , et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354 (9194) 1940-1947
• 42 Fremes SE, Wong BI, Lee E , et al. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58 (6) 1580-1588
• 43 Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62 (15) 2193-2211
• 44 Mangano DT, Tudor IC, Dietzel C ; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354 (4) 353-365
• 45 Hiatt WR. Observational studies of drug safety—aprotinin and the absence of transparency. N Engl J Med 2006; 355 (21) 2171-2173
• 46 Fergusson DA, Hébert PC, Mazer CD , et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358 (22) 2319-2331
• 47 Shakur H, Roberts I, Bautista R , et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734) 23-32
• 48 Ubbink DT, Vermeulen H, Knops AM , et al. Implementation of evidence-based practice: outside the box, throughout the hospital. Neth J Med 2011; 69 (2) 87-94